Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (481-490 of 566) with videos related to

Pageof 57
Sort By:
Leukemia|March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2020
Implications of MYC Rearrangements in Newly Diagnosed Multiple MyelomaNadine Abdallah, Linda B Baughn, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2019
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
Mayo Clinic Proceedings|March 6, 2021
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
American Journal of Hematology|August 12, 2017
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trialsArjun Lakshman, Jithma P Abeykoon, Shaji K Kumar, et al.
Blood Cancer Journal|August 13, 2020
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseNadine Abdallah, S Vincent Rajkumar, Patricia Greipp, et al.
Pageof 57

Showing results (481-490 of 566) with videos related to

Sort By:
Pageof 57
Leukemia|March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2020
Implications of MYC Rearrangements in Newly Diagnosed Multiple MyelomaNadine Abdallah, Linda B Baughn, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2019
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
Mayo Clinic Proceedings|March 6, 2021
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
American Journal of Hematology|August 12, 2017
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trialsArjun Lakshman, Jithma P Abeykoon, Shaji K Kumar, et al.
Blood Cancer Journal|August 13, 2020
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseNadine Abdallah, S Vincent Rajkumar, Patricia Greipp, et al.
Pageof 57